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We report the case of an HIV-positive female patient with neurofibromatosis type 1 who was 
treated for recurrent peptic ulcer disease and later developed diabetes mellitus and chronic 
diarrhoea. A metastasising somatostatinoma was histologically proven and evidence of a 
concomitant gastrin-producing neuroendocrine tumour was found. Neuroendocrine tumours 
(NETs) are very rare neoplasms originating from a wide variety of endocrine and nervous 
system tissue with the ability to produce different hormones. A somatostatin- and gastrin-
secreting NET in a patient with HIV has not been reported in the literature, to the best of 
our knowledge. We discuss oncogenic pathomechanisms related to the underlying conditions 
and propose stringent monitoring for tumours in HIV-positive patients with phakomatoses as 
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Neuroendocrine tumours (NETs) are neoplasms originating from a wide variety of endocrine 
and nervous system tissues with the ability to produce different hormones. Pancreatic hormone-
producing NETs are often associated with specific clinical manifestations, resulting from the 
excessive production and action of the respective hormone.
We report on a 30-year-old HIV-positive female patient with neurofibromatosis type 1 (NF1) who 
presented with Zollinger-Ellison syndrome and later developed diabetes mellitus and chronic 
diarrhoea. A somatostatinoma was proven histologically and we found laboratory evidence for 
the concomitant production of gastrin by the tumour. Somatostatinomas are very rare tumours, 
and a somatostatin- and gastrin-secreting NET in a patient with HIV has not been reported. We 
discuss oncogenic pathomechanisms related to the underlying conditions and propose stringent 
monitoring for tumours in HIV-positive patients with phakomatoses.
Case presentation
A 30-year-old woman had been seen at the Surgical Department over the past five years for 
recurrent upper gastro-intestinal bleeds. Peptic ulcer disease was proven gastroscopically on four 
occasions. She was repeatedly treated with proton-pump inhibitors and on one occasion received 
empiric triple therapy for Helicobacter pylori eradication. Her past medical history included visits 
to the Plastic Surgery Department for removal of a plexiform neurofibroma with enucleation of 
her right eye.
Clinically, with numerous neurofibromata, one big plexiform neurofibroma on the right side of 
her face, several café-au-lait spots and axillary freckling, she fulfilled the criteria for NF1.1 She 
had tested HIV-positive a few months earlier, with a baseline CD4 count of 290 cells/µL. One 
week prior to admission, diabetes mellitus was diagnosed by the local primary healthcare clinic 
and she was started on metformin 850 mg bd. She then presented to the Medical Department with 
a four-day history of diarrhoea without melaena or epigastric pain.
On admission, she was moderately dehydrated with features of NF1 (Figures 1a and 1b). The 
rest of the clinical examination was normal. A chest X-ray was unremarkable, and blood results 
were essentially normal except for a thrombocytosis of 614 x 109 cells/L. The patient received 
intravenous fluids and antibiotics. Insulin was commenced and antiretroviral therapy (ART) 
with TDF, 3TC and EFV was started.
Abdominal ultrasound demonstrated several solid, round lesions in the liver that were 
confirmed on computed tomography (Figure 1c). Liver biopsy showed polygonal tumour cells 
with granular eosinophilic cytoplasm and monomorphic nuclei, coarse dispersed chromatin 
and focal glandular formations. Synaptophysin and chromogranin stains were positive, 
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compatible with a metastatic neuroendocrine carcinoma. 
Special somatostatin staining was positive, proving the 
somatostatinoma (Figure 2a and 2b). The excessively 
increased fasting gastrin level of 19 577 ng/L (13 ng/L – 
115 ng/L) strongly suggested the additional hypersecretion 
of gastrin by the tumour.
A malignant, metastatic neuroendocrine tumour secreting 
somatostatin and gastrin was diagnosed. Unfortunately, the 
patient died soon after diagnosis.
Discussion
Somatostatinomas are extremely rare neuroendocrine 
tumours with an estimated annual incidence of 1 in 40 
million per year, arising from the delta cells in the pancreas 
or, in about 40% of cases, from the duodenum.2 Gender 
distribution is equal and mean age at presentation is between 
51 and 53 years. Occasionally, additional hormones such as 
glucagon, calcitonin, insulin, gastrin or others are produced. 
Somatostatinomas often metastasise early and present late, 
resulting in a poorer prognosis.2 Whilst non-metastatic 
somatostatinomas with full tumour resection can be cured, 
metastatic forms often have a fatal course as they are diagnosed 
late. Appropriate surgery combined with chemotherapy 
results in an average 5-year survival of about 59.9%.2
The association between NF1 and somatostatinomas is well 
documented. Fendrich et al. reported a case of NF1 and a 
duodenal somatostatinoma, and found 36 other cases in the 
literature until 2004, of which only 14 involved metastasis.3 
Somatostatinomas in NF1 occur with a higher frequency and 
are located more often in the duodenum than in patients 
without NF1, in whom pancreatic tumours dominate. NETs 
located in the duodenum tend to present less often with a 
somatostatinoma syndrome but rather with local or non-
specific symptoms.3
Most somatostatinomas are symptomatic. The full clinical 
picture of the somatostatinoma syndrome, characterised as an 
inhibitory syndrome, was initially reported by Krejs et al. in 
1979.4 It comprises diabetes mellitus (suppression of insulin), 
steatorrhoea and cholelithiasis (inhibition of cholecystokinin 
and biliary motility). Additionally, patients often have 
general symptoms such as nausea and vomiting, abdominal 
pain and weight loss. Duodenal somatostatinomas might 
present with abdominal pain, duodenal obstruction, gastro-
intestinal bleeding or jaundice, owing to local growth of the 
tumour.2
The differential diagnosis is wide, depending on the patient’s 
presentation. It includes, amongst others, refractory diabetes 
mellitus and other endocrine conditions, carcinoids and 
gastro-intestinal malignancies, pancreatitis, inflammatory 
bowel disease, coeliac disease, irritable bowel syndrome or 
even depression.
NF1, originally described by Friedrich von Recklinghausen in 
1882, is a fairly common hereditary disease that is autosomal-
dominantly inherited and occurs in 1:3500 births. It forms 
part of the neuro-cutaneous syndromes or phakomatoses, a 
group of genetic conditions predominantly involving tissues 
of ectodermal origin, mainly the nervous system, skin and 
eye. NF1 is characterised by the slow evolution of tumour 
lesions in childhood and adolescence, as well as by a tendency 
to form hamartomas and a disposition to fatal malignant 
transformation. The mutated gene, encoding the protein 
neurofibromin (17q11.2), is a tumour-suppressor gene.
Involved mechanisms are rat sarcoma viral oncogene 
homologue (RAS)-mitogen activated protein kinase (MAPK), 
a b
c
Source: Photographs of Patient and CT Abdomen taken by Juliane Hiesgen with the patient’s 
consent
FIGURE 1: Clinical features of NF 1, with numerous neurofibromata (a), big 
plexiform neurofibroma over the right side of the face (b) and (c) CT image 
showing several hypodense lesions in the liver parenchyma, suggestive of 
metastases.
ba
Source: Photographs of Histological Specimens by kind permission of Dr T. Omar
FIGURE 2: Histological slides from liver lesions: (a) HE staining showing 
polyglandular tumour cells with granular eosinophilic cytoplasm and glandular 
formation and (b) strongly positive immuno-histochemical synaptophysin stain 
(specific for neuroendocrine tumours).
Page 3 of 4 Case Report
http://www.sajhivmed.org.za doi:10.4102/sajhivmed.v16i1.323
mammalian target of rapamycin (mTOR) and P21 protein 
(Cdc42/Rac)-activated kinase (PAK1).5 Patients with this 
disorder are predisposed to both benign and malignant 
tumours of neurogenic and non-neurogenic origin. NF1 
reduces average life expectancy by 10–15 years, with 
malignant tumours being the most common cause of death.
In addition to NF1, our patient was HIV-positive with a 
low CD4 count. HIV infection is strongly associated with 
specific malignancies. Kaposi’s sarcoma (KS), non-Hodgkin 
lymphomas (NHLs) and invasive cervical cancer are AIDS-
defining illnesses.6
Several non-AIDS-defining malignancies appear more 
common amongst HIV-positive patients, and their incidence 
is increasing; these include invasive anal carcinoma, Hodgkin 
lymphomas, skin cancers, leukaemia, lung cancer, multiple 
myeloma, prostate cancer and others.7,8,9,10,11
Different pathomechanisms, direct and indirect, are 
involved in the oncogenesis in HIV. Opportunistic co-
infections with oncogenic viruses can result in HIV-
associated malignancies. Here the role of viral encoded 
micro-RNA is under investigation.12 In particular, the 
associations of Kaposi’s sarcoma and primary effusion NHL 
with human herpes virus type 8 (HHV 8), of primary CNS 
lymphoma and NHL with Epstein-Barr virus (EBV) and of 
invasive cervical cancer with human papillomavirus (HPV) 
are well documented.13,14,15
Immune deficiency itself seems to play a role in HIV 
malignancies.16 Impaired T-cell surveillance in particular 
may lead to insufficient elimination of transformed cells, 
resulting in oncogenesis. Furthermore, the HIV TAT protein, 
a nonstructural protein secreted by infected cells and 
taken up by uninfected cells, seems to be involved in the 
pathomechanism of HIV-related malignancies. It has been 
found to deregulate cellular genes (as pRb2/p130) that work 
as onco-suppressor proteins.17,18
Recently, hyperactivation of mTOR has been found to play 
a role in different aspects of HIV pathology including HIV-
associated nephropathy (HIVAN), HIV encephalopathy, and 
HIV-associated and non-HIV-associated malignancies.19,20 As 
mentioned above, the mTOR pathway disinhibition is also 
one of the pathomechanisms involved in the oncogenesis 
in NF1. Additional mTOR activation in the setting of HIV 
infection as a compounding contributor may confer a ’second 
hit’, leading to the question of the potential use of mTOR 
inhibitors in the treatment of these patients. This point also 
raises the interesting question of whether HIV patients with 
an increased risk for malignancies develop these at earlier 
ages and whether these tumours are more aggressive.
Conclusion
People living with HIV and/or AIDS have a significantly 
increased risk of developing malignancies, as have patients 
with neurofibromatosis (and other phakomatoses). Different 
mechanisms are involved in these two independent pro-
oncogenic diseases, and there are no data on incidence or 
prevalence rates for patients affected by both conditions. We 
assume that these rates might be higher than for HIV or NF1 
alone.
Therefore, in a setting of high HIV prevalence – such as 
South Africa – we suggest regular HIV testing in patients 
with NF1 and other phakomatoses. Frequent follow-up 
(e.g. 6-monthly) with close monitoring for malignancies and 
further diagnostic work-up, where a tumour is suspected, 
is encouraged. Because the risk resulting from the genetic 
condition is not modifiable, the aim can only be to reduce the 
tumour risk from HIV infection and immunosuppression. 
We therefore recommend starting ARVs irrespective of CD4 
counts in such patients.
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